Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome

T. Fujihara, T. Takeuchi, K. Tsubota, N. Kayagaki, H. Yagita, K. Okumura, T. Abe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The aim of the study was to elucidate the involvement of Fas antigen in human autoimmune disease, by analysing serum levels of soluble Fas/APO1 protein in patients with various autoimmune diseases, including system lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), Behcet's syndrome and Sjogren's syndrome (SjS). The levels of soluble Fas/APO-1 in sera were quantitated by a sandwich enzyme-linked immunosorbent assay. Soluble Fas/APO-1 levels were significantly increased in serum from patients with primary Sjogren's syndrome (1°SjS) compared with control subjects. However, no significant differences in soluble Fas/APO-1 levels were noted in patients with secondary Sjogren's syndrome (2°SjS) nor in patients with any of the other autoimmune diseases. The soluble Fas/APO-1 level in 1°SjS patients with extraglandular diseases was significantly higher than that in patients without extraglandular diseases. These results suggest that soluble Fas/APO-1 protein may play an important role in the pathogenesis of 1°SS.

Original languageEnglish
Pages (from-to)496-499
Number of pages4
JournalClinical Rheumatology
Volume17
Issue number6
DOIs
Publication statusPublished - 1998 Jan 1
Externally publishedYes

Keywords

  • Autoimmune disease
  • Enzyme-linked immunosorbent assay
  • Sjogren's syndrome
  • Soluble Fas/APO-1 protein

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Serum soluble Fas/APO-1 is increased in patients with primary Sjogren's syndrome'. Together they form a unique fingerprint.

  • Cite this